Fosravuconazole L-lysine ethanolate, Inhibitor

Fosravuconazole L-lysine ethanolate

Cat. Num. AAA5765005

• Purity: 0.95
• Synonyms: Fosravuconazole L-lysine ethanolate; E-1224 L-lysine ethanolate; BMS-379224 L-lysine ethanolate; inhibitor

• Purity/Purification: 0.95
• Form/Format: Solid

• Solubility: DMSO: 48mg/mL (64.89mM); (<1mg/ml refers to the product slightly soluble or insoluble)
• SMILES: N#CC1=CC=C(C2=CSC([C@H](C)[C@@](OCOP(O)(O)=O)(C3=CC=C(F)C=C3F)CN4N=CN=C4)=N2)C=C1.CCO.N[C@H](C(O)=O)CCCCN
• Formula: C31H40F2N7O8PS
• In vitro: Fosravuconazole (E-1224; 10-50 mg/kg; oral administration; daily; for 20 days) treatment suppresses the parasitemia and prevents death in mice infected with the T. cruzi Y strain[2].
• CAS Number: 914361-45-8
• Preparation and Storage: Store at 0-4 degree C for short term (days to weeks), or -20 degree C for long term (months).

Chemical Structure

Related Product Information for Fosravuconazole L-lysine ethanolate, inhibitor

FosravuconazoleL-lysine ethanolate is a broad-spectrum antifungal agent. In Japan, it is approved for the treatment of onychomycosis, a fungal infection of the nail. It is a prodrug that is converted into ravuconazole.

References

Diniz LF, Mazzeti AL, Caldas IS, Ribeiro I, Bahia MT. Outcome of E1224-Benznidazole Combination Treatment for Infection with a Multidrug-Resistant Trypanosoma cruzi Strain in Mice. Antimicrob Agents Chemother. 2018;62(6):e00401-18. Published 2018 May 25. doi:10.1128/AAC.00401-18Watanabe S, Tsubouchi I, Okubo A. Efficacy and safety of fosravuconazole L-lysine ethanolate, a novel oral triazole antifungal agent, for the treatment of onychomycosis: A multicenter, double-blind, randomized phase III study. J Dermatol. 2018;45(10):1151-1159. doi:10.1111/1346-8138.14607
Diniz, Livia, de, et al. Outcome of E1224-Benznidazole Combination Treatment for Infection with a Multidrug-Resistant Trypanosoma cruzi Strain in Mice[J]. Antimicrobial Agents & Chemotherapy, 2018.